This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis.  New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.